NEW YORK and SYDNEY, Australia, November 18, 2021 (GLOBE NEWSWIRE) - Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), an Australia-based diversified biopharmaceutical enterprise focused on the research,…
NEW YORK and SYDNEY, Australia, October 28, 2021 (GLOBE NEWSWIRE) - Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), an Australia-based biopharmaceutical enterprise, today announced that its article…
In order to enhance the cohesiveness and centripetal force of Beroni team and enrich the cultural life of employees, Beroni Group organized a team building activity with the theme of…
September 25-27, 2021, the sixth “China BioMed Innovation and Investment Conference(CBIIC)” was successfully held in Suzhou. With cutting-edge scientific research and advanced medical projects, the scientific research team of Beroni…
NEW YORK and SYDNEY, Australia, Aug. 31, 2021 -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni”), an Australia-based biopharmaceutical enterprise, announced the latest clinical study of its SARS-CoV-2 Antigen Test…
NEW YORK and SYDNEY, Australia, August 18, 2021 - Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni”), an Australia-based diversified biopharmaceutical enterprise, announced that PENAO Pty Ltd, its majority-owned, Sydney-based anti-cancer…
NEW YORK and SYDNEY, Australia, May 28, 2021 - Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni”), an Australia-based diversified biopharmaceutical enterprise today announced that it has signed a Memorandum of…
NEW YORK and SYDNEY, April 27, 2021, Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni”), an Australia-based diversified biopharmaceutical enterprise today announced that it has received the notification that its SARS-CoV-2 Antigen Test…
